The Problem

Each year, 18 million people are diagnosed with cancer.

Surgery remains the best treatment option, but survival rates are too low.

The current approach to screening cancer margins isn't working

Today, hospitals use a lengthy diagnostic process called "frozen sections" that involves freezing the tissue, cutting it into thin slices and waiting on an on-call pathologist to provide an analysis using a 100+ year old method.

Inconclusive
Slow
Recurrence
Our Approach

Accurate cancer removal, the first time

We’re combining our proprietary MasSpec Pen technology with cutting-edge mass spectrometry, sophisticated pattern recognition, and data analytics to transform cancer surgery.

Rapid

Results in seconds

Direct

In situ analysis
 without labels or agents

Precise

Helping surgeons make informed decisions

How it works

We're developing a device for surgical decision support

MasSpec PenTM

Our proprietary MasSpec Pen technology touches the tissue and extracts molecules that are diagnostic to the disease state and delivers those molecules to a mass spectrometer for analysis.

Mass Spectrometer

The mass spectrometer generates 1000s of signals per second that are related to the tissue of interest.

Clinical Decision Support

Our proprietary data analytics and AI/ML algorithms analyze the data in real-time and present a clinical risk score to the user.

Scientific Evidence

We have a growing body of scientific publications and clinical data

Peer-reviewed publications

Lung cancer impact:

* Science Translational Medicine, 2017

Accuracy

96.8%

Sensitivity

97.9%

Specificity

95.7%